clinicians preference when semaglutide is not suitable for the treatment of overweight and obesity: A review Oral Semaglutide vs. Injectable: Which

During clinical trials, people took Wegovy for 68 weeks (15 months)

What are macronutrients

Clinical evidence remains evolving

Common side effects include: Gastrointestinal: Nausea, diarrhea, constipation, and abdominal pain (most common, usually transient) Decreased appetite: Expected and generally beneficial for weight management Injection site reactions: Mild redness or irritation at the injection site Rare but serious risks include: Pancreatitis (inflammation of the pancreas seek immediate medical attention for severe abdominal pain) Gallbladder disease Potential thyroid tumor risk (based on animal studies

For example: A patient with high fasting insulin may respond differently than one with pancreatic beta-cell dysfunction A patient with fatty liver disease may experience additional metabolic benefitsor complicationsdepending on hepatic status This is precisely why baseline lab testing is not optionalit is foundational